Technology type | Forecasting group | Total | |||||
Commercial organisation | Consultancy agency | Governmental agency | Independent non-profit organisation | Researchers | Policy research group | ||
Assistive devices | 3 (3.2%) | 0 (0.0%) | 1 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (0.6%) |
Devices and biomaterials | 16 (16.8%) | 6 (10.9%) | 56 (15.6%) | 3 (17.6%) | 7 (11.5%) | 10 (10.1) | 98 (14.3%) |
Diagnostic tests and imaging | 6 (6.3%) | 26 (47.3%) | 63 (17.6%) | 3 (17.6%) | 9 (14.8%) | 24 (24.2%) | 131 (19.1) |
Drugs (non- prophylactic vaccine) | 7 (7.4%) | 2 (3.6%) | 31 (8.7%) | 1 (5.9%) | 22 (36.1%) | 19 (19.2%) | 82 (12.0%) |
IT systems, eHealth, mHealth | 18 (18.9%) | 7 (12.7%) | 43 (12.0%) | 3 (17.6%) | 3 (4.9%) | 12 (12.1%) | 86 (12.6%) |
Medical equipment | 2 (2.1%) | 5 (5.5%) | 31 (8.7%) | 0 (0.0%) | 1 (1.6%) | 0 (0.0%) | 37 (5.4%) |
Non-surgical therapy | 1 (1.1%) | 0 (0.0%) | 9 (2.5%) | 1 (5.9%) | 3 (4.9%) | 1 (1.0%) | 15 (2.2%) |
Population programme | 5 (5.3%) | 0 (0.0%) | 9 (2.5%) | 3 (17.6%) | 1 (1.6%) | 6 (6.1%) | 24 (3.5%) |
Prophylactic vaccine | 0 (0.0%) | 0 (0.0%) | 18 (5.0%) | 0 (0.0%) | 0 (0.0%) | 6 (6.1%) | 24 (3.5%) |
Regenerative medicine | 22 (23.2%) | 1 (1.8%) | 48 (13.4%) | 1 (5.9%) | 4 (6.6%) | 4 (4.0%) | 80 (11.7%) |
Therapeutic procedure | 0 (0.0%) | 1 (1.8%) | 20 (5.6%) | 0 (0.0%) | 6 (9.8%) | 9 (9.1%) | 36 (5.3%) |
Organisational programme | 2 (2.1%) | 10 (10.6%) | 11 (3.1%) | 1 (5.9%) | 4 (6.6%) | 2 (2.0%) | 26 (3.8%) |
Unknown | 9 (9.5%) | 2 (3.6%) | 16 (4.5%) | 1 (5.9%) | 1 (1.6%) | 4 (4.0%) | 33 (4.8%) |
Others | 4 (4.2%) | 1 (1.8%) | 2 (0.6%) | 0 (0.0%) | 0 (0.0%) | 2 (2.0%) | 9 (1.3%) |
Total | 95 (100%) | 55 (100%) | 358 (100%) | 17 (100%) | 61 (100%) | 99 (100%) | 685 (100%) |
IT, information technology; eHealth, electronic health; mHealth, mobile health.